In a recent announcement on August 13, 2026, MapLight Therapeutics, Inc., listed on Nasdaq as MPLT, has disclosed a new initiative. The clinical-stage biopharmaceutical company, with headquarters in both San Francisco and Boston, aims to enhance the quality of life for individuals dealing with severe central nervous system disorders. Through a securities purchase agreement, they have partnered with institutional and accredited investors for a private placement financing (the “PIPE”), resulting in a substantial gross profit of about $150 million. This total amount is before any deductions for placement agent fees and anticipated offering expenses. The financing round is notably backed by a combination of fresh investors as well as existing institutional supporters.